title: Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
authors.forename: Rym
authors.initials: R
authors.lastname: Ennaifer
authors.forename: Myriam
authors.initials: M
authors.lastname: Cheikh
authors.forename: Hayfa
authors.initials: H
authors.lastname: Romdhane
authors.forename: Rania
authors.initials: R
authors.lastname: Hefaiedh
authors.forename: Houda
authors.initials: H
authors.lastname: Ben Nejma
authors.forename: Najet
authors.initials: N
authors.lastname: Bel Hadj
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000209:etiology* / Q000276:immunology; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*; D012720:Severity of Illness Index
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a